共 15 条
[1]
Bone R.C., The pathogenesis of sepsis, Ann Intern Med, 115, pp. 457-492, (1991)
[2]
Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis, Crit Care Med, 20, pp. 864-874, (1992)
[3]
Parrillo J.E., Pathogenetic mechanism of septic shock, N Engl J Med, 328, pp. 1471-1477, (1993)
[4]
The problem of sepsis, Intensive Care Med, 20, pp. 300-304, (1994)
[5]
Knaus W.A., Sun X., Nystrom P.O., Wagner D.P., Evaluation of definitions for sepsis, Chest, 101, pp. 1656-1662, (1992)
[6]
Ziegler E.J., Fisher C.J., Sprung C.L., Et al., Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin, N Engl J Med, 324, pp. 429-436, (1991)
[7]
Greenman R.L., Schein R.M.H., Martin M.A., Et al., A controlled trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram negative sepsis, JAMA, 266, pp. 1097-1102, (1991)
[8]
Vincent J.L., Bakker J., Marecaux G., Schandene L., Kahn R.J., Dupont E., Administration of anti-TNF antibody improves left ventricular function in septic shock patients, Chest, 101, pp. 810-815, (1991)
[9]
Fisher C.J., Opal S.M., Dhainaut J.F., Stephens S., Zimmerman J.L., Nightngale P., Harris S.J., Schein R.M.H., Panacek E.A., Vincent J.L., Foulke G.E., Warren E.L., Guarard C., Park G., Bodmer M.W., Cohen J., Van der Linden C., Cross A.S., Sadoff J.C., Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis, Crit Care Med, 21, pp. 318-327, (1993)
[10]
Fisher C.J., Slotman G.J., Opal S.M., Pribble J., Bohe R.C., Emanuel G., Ng D., Bloedow D.C., Catalano M.A., Initial evaluation of human recombinant interleukin receptor antagonist in the treatment of sepsis syndrome: a randomized, open label, placebo controlled multicenter trial, Crit Care Med, 22, pp. 12-21, (1994)